Spark Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ONCE and buy or sell other stocks, ETFs, and their options commission-free!

About ONCE

Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. 

CEO
Sylke Poehling, Ph.D
CEOSylke Poehling, Ph.D
Employees
Employees
Headquarters
Philadelphia, Pennsylvania
HeadquartersPhiladelphia, Pennsylvania
Founded
2013
Founded2013
Employees
Employees

ONCE Key Statistics

Market cap
4.29B
Market cap4.29B
Price-Earnings ratio
-17.35
Price-Earnings ratio-17.35
Dividend yield
Dividend yield
Average volume
601.86K
Average volume601.86K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$114.20
52 Week high$114.20
52 Week low
$34.53
52 Week low$34.53

Stock Snapshot

With a market cap of 4.29B, Spark Therapeutics(ONCE) trades at $113.57. The stock has a price-to-earnings ratio of -17.35.

During the trading day, Spark Therapeutics(ONCE) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading volume for Spark Therapeutics(ONCE) stock has reached 0, versus its average volume of 601.86K.

The stock's 52-week range extends from a low of $34.53 to a high of $114.20.

The stock's 52-week range extends from a low of $34.53 to a high of $114.20.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.